pharmaphorum media

pharmaphorum.com

pharmaphorum media drives better communication and collaboration between the pharmaceutical industry and other healthcare stakeholders.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

AS BREXIT TRIGGER NEARS, UK PHARMA PREPARES FOR DIFFERENT SCENARIOS

pharmaphorum media | February 03, 2017

news image

Theresa May’s government yesterday published its White Paper after having easily secured a majority vote in the House of Commons to trigger Article 50 and begin the Brexit process earlier in the day. The White Paper doesn’t carry much new detail, and is mainly drawn from the prime minister’s speech last month. This made it clear that the UK would seek a ‘clean break’ and leave the single market and customs union, and then seek to negotiate deals on trade and co-operation from there....

Read More

PFIZER BREAST CANCER DRUG IBRANCE REJECTED BY NICE

pharmaphorum media | February 03, 2017

news image

The decision confirms the company’s fears that the drug would fare badly under the cost-effectiveness body’s assessment. Pfizer’s UK medical director, David Montgomery, told pharmaphorum in November that he feared NICE might reject Ibrance (palbociclib), as it is an add-on therapy....

Read More

PHARMA CEOS UNDER SCRUTINY AFTER TRUMP MEETING

pharmaphorum media | February 02, 2017

news image

Analysts all wanted to know the industry leaders’ impressions of Trump, and his claims that pharma has been “getting away with murder” on pricing. The CEOs sought to put a positive spin on the meeting, which took place on Tuesday, saying that Trump understood the importance of the innovative pharma industry....

Read More

FDA FAST TRACKS SHIRE CLOTTING DISEASE DRUG

pharmaphorum media | March 23, 2017

news image

The US regulator has given a Fast Track designation to a Shire pipeline drug for a life-threatening blood clotting disease, hereditary thrombotic thrombocytopenic purpura....

Read More
news image

AS BREXIT TRIGGER NEARS, UK PHARMA PREPARES FOR DIFFERENT SCENARIOS

pharmaphorum media | February 03, 2017

Theresa May’s government yesterday published its White Paper after having easily secured a majority vote in the House of Commons to trigger Article 50 and begin the Brexit process earlier in the day. The White Paper doesn’t carry much new detail, and is mainly drawn from the prime minister’s speech last month. This made it clear that the UK would seek a ‘clean break’ and leave the single market and customs union, and then seek to negotiate deals on trade and co-operation from there....

Read More
news image

PFIZER BREAST CANCER DRUG IBRANCE REJECTED BY NICE

pharmaphorum media | February 03, 2017

The decision confirms the company’s fears that the drug would fare badly under the cost-effectiveness body’s assessment. Pfizer’s UK medical director, David Montgomery, told pharmaphorum in November that he feared NICE might reject Ibrance (palbociclib), as it is an add-on therapy....

Read More
news image

PHARMA CEOS UNDER SCRUTINY AFTER TRUMP MEETING

pharmaphorum media | February 02, 2017

Analysts all wanted to know the industry leaders’ impressions of Trump, and his claims that pharma has been “getting away with murder” on pricing. The CEOs sought to put a positive spin on the meeting, which took place on Tuesday, saying that Trump understood the importance of the innovative pharma industry....

Read More
news image

FDA FAST TRACKS SHIRE CLOTTING DISEASE DRUG

pharmaphorum media | March 23, 2017

The US regulator has given a Fast Track designation to a Shire pipeline drug for a life-threatening blood clotting disease, hereditary thrombotic thrombocytopenic purpura....

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us